4 completed, 4 terminated. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 4, Terminated 4 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow VTX-2337: new trials by email Literature Review of VTX-2337 trials Research Report on VTX-2337
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer VTX-2337, Nivolumab - Carcinoma, Squamous Cell | Phase 1 | Terminated | Celgene | 15 | 2019-07-03 | 2023-02-24 |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim - Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Terminated | Mayo Clinic | 4 | 2016-02-05 | 2018-09-05 |
| Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer Durvalumab, Pegylated Liposomal Doxorubicin, Motolimod - Ovarian Cancer | Phase 1 / Phase 2 | Completed | Ludwig Institute for Cancer Research | 53 | 2015-12-02 | 2022-10-10 |
| A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab Motolimod, Cetuximab, Nivolumab - Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Terminated | Celgene | 18 | 2014-10-28 | 2019-10-25 |
| VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas VTX-2337 plus radiotherapy - Low Grade B Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Celgene | 2 | 2011-07-01 | 2019-09-25 |
| TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck TLR8 agonist VTX-2337, cetuximab, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Completed | University of Washington | 13 | 2011-06-01 | 2015-03-05 |
| TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer TLR8 Agonist VTX-2337, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study - Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor | Phase 1 | Completed | Gynecologic Oncology Group | 20 | 2011-03-01 | 2014-12-25 |
| Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer VTX-2337 - Advanced Solid Tumors, Lymphoma | Phase 1 | Completed | Celgene | 33 | 2008-11-07 | 2019-09-25 |
Lymphoma (2) · Ovarian Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Breast Neoplasms (1) · Brenner Tumor (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Head and Neck Neoplasms (1) · Melanoma (1) · Pancreatic Neoplasms (1) · Salivary Gland Neoplasms (1) · Tongue Neoplasms (1)
Celgene (4) · Gynecologic Oncology Group (1) · Ludwig Institute for Cancer Research (1) · Mayo Clinic (1) · University of Washington (1)
United States (8) · Switzerland (1)
Amar Patel, MD (3) · Bradley J Monk, MD (1) · Bradley Monk (1) · George Coukos, MD, PhD (1) · Laura Chow (1) · Peter Cohen (1)
P30CA015083 (1), P30CA015704 (1), U10CA027469 (1)